CDKN2A and non-small cell lung carcinoma: Thus, real-world datapoints indicative of progression align with our survival results and in total suggest that CDKN2A deletion is a potential biomarker for selecting between mono-IO and chemo-IO regimens in advanced non-squamous NSCLC.